Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Shielding against radiation will not only help people survive nuclear fallout but also improve health outcomes for cancer ...

Hundreds of people with aggressive blood cancer will be offered a groundbreaking one-off personalised therapy that ...

Combining an existing small-molecule protein therapy called tumor necrosis factor related apoptosis-inducing ligand with ...

When added to chemotherapy, researchers found no significant difference in overall or progression-free survival between PD-1 ...

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, today presented positive, final data from the ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

In a sense, every investor is a growth investor. Even those who are primarily seeking income enjoy when the stocks they buy ...